ANL 34.10 Decreased By ▼ -0.15 (-0.44%)
ASC 13.65 Increased By ▲ 0.30 (2.25%)
ASL 23.40 Increased By ▲ 0.80 (3.54%)
AVN 85.60 Increased By ▲ 1.90 (2.27%)
BOP 7.70 No Change ▼ 0.00 (0%)
BYCO 9.44 Increased By ▲ 0.07 (0.75%)
DGKC 111.51 Increased By ▲ 1.31 (1.19%)
EPCL 48.99 Decreased By ▼ -1.90 (-3.73%)
FCCL 22.85 Increased By ▲ 0.09 (0.4%)
FFBL 25.47 Decreased By ▼ -0.23 (-0.89%)
FFL 15.33 Increased By ▲ 0.03 (0.2%)
HASCOL 8.94 Decreased By ▼ -0.06 (-0.67%)
HUBC 78.43 Decreased By ▼ -0.57 (-0.72%)
HUMNL 6.13 Increased By ▲ 0.29 (4.97%)
JSCL 19.14 Increased By ▲ 0.44 (2.35%)
KAPCO 40.50 Increased By ▲ 1.11 (2.82%)
KEL 3.72 Increased By ▲ 0.04 (1.09%)
LOTCHEM 14.20 Decreased By ▼ -0.15 (-1.05%)
MLCF 42.75 Increased By ▲ 0.45 (1.06%)
PAEL 30.90 Decreased By ▼ -0.17 (-0.55%)
PIBTL 9.52 Increased By ▲ 0.07 (0.74%)
POWER 8.61 Increased By ▲ 0.17 (2.01%)
PPL 82.50 Decreased By ▼ -0.80 (-0.96%)
PRL 23.09 Increased By ▲ 0.32 (1.41%)
PTC 9.00 Decreased By ▼ -0.20 (-2.17%)
SILK 1.38 Decreased By ▼ -0.02 (-1.43%)
SNGP 38.90 Increased By ▲ 0.31 (0.8%)
TRG 165.00 Increased By ▲ 1.78 (1.09%)
UNITY 35.80 Increased By ▲ 0.87 (2.49%)
WTL 1.53 Increased By ▲ 0.08 (5.52%)
BR100 4,846 Increased By ▲ 46.43 (0.97%)
BR30 24,817 Increased By ▲ 123.55 (0.5%)
KSE100 45,175 Increased By ▲ 231.06 (0.51%)
KSE30 18,470 Increased By ▲ 86.89 (0.47%)

Coronavirus
VERY HIGH
Pakistan Deaths
18,993
7824hr
Pakistan Cases
861,473
344724hr
Sindh
292,644
Punjab
319,365
Balochistan
23,447
Islamabad
78,200
KPK
124,484
World

China's Sinovac COVID-19 vaccine appears safe in last stage trials: Researchers

  • Butantan Institute states CoronaVac proved to be safe in a trial so far involving 9,000 volunteers
Updated 20 Oct 2020

(Karachi) In a last stage clinical trial, an experimental coronavirus vaccine developed by China's Sinovac Biotech appeared to be safe, preliminary results showed.

Brazil's leading bio-medical research centre Butantan Institute engaged in carrying out the Phase 3 tests, said the two-dose vaccine, called CoronaVac, proved to be safe in a trial so far involving 9,000 volunteers.

But the research institute's director Dimas Covas said that results of the data on vaccine's effectiveness will not be released till completion of the trial. The trial is being conducted on 13,000 volunteers.

He stated that researchers will keep monitoring the participants in the on-going trial. He mentioned there were no severe adverse reactions to the vaccine, with 20% of the volunteers reporting mild pain

It's the first set of results of Sinovac's Phase 3 global trials, which are also being conducted in Turkey and Indonesia.

Earlier, the China-based biopharmaceutical company Sinovac Biotech started Phase III clinical trial of its inactivated Covid-19 vaccine in Turkey. The company has already performed Phase I/II studies of the vaccine in volunteers aged 18 to 59 years and those aged 60 years old and above, at Jiangsu and Hebei Provinces on April 16 and May 22, respectively, in China.